1. Home
  2. SXTP vs GOVX Comparison

SXTP vs GOVX Comparison

Compare SXTP & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 60 Degrees Pharmaceuticals Inc.

SXTP

60 Degrees Pharmaceuticals Inc.

HOLD

Current Price

$1.49

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$2.10

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXTP
GOVX
Founded
2010
2001
Country
United States
United States
Employees
3
17
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9M
4.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SXTP
GOVX
Price
$1.49
$2.10
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$14.10
$1.00
AVG Volume (30 Days)
54.8K
9.2M
Earning Date
05-15-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$33.92
N/A
Revenue Next Year
$51.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.12
52 Week High
$8.62
$4.40

Technical Indicators

Market Signals
Indicator
SXTP
GOVX
Relative Strength Index (RSI) 44.87 52.14
Support Level $1.30 $0.70
Resistance Level $1.52 $4.40
Average True Range (ATR) 0.09 0.58
MACD 0.02 0.06
Stochastic Oscillator 54.51 28.71

Price Performance

Historical Comparison
SXTP
GOVX

About SXTP 60 Degrees Pharmaceuticals Inc.

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: